A plasma proteomic atlas of rare genetic neurodevelopmental disorders reveals convergent molecular signatures, neurodegenerative overlap, and a cross-disorder severity index

Rare genetic neurodevelopmental disorders are individually too small for well-powered biomarker studies, and each is typically studied alone. We present a harmonized plasma proteomic resource that treats them together: over 10,000 proteins measured across 27 rare genetic neurodevelopmental disorders and unaffected family members, 26 of them with enough participants for differential abundance analysis, paired with standardized adaptive behaviour phenotypes and released with the full analysis pipeline. Aggregating across disorders makes shared biology visible that single-disorder studies cannot resolve. Genetically distinct disorders converge onto two proteomic clusters separated along a single dominant axis, distinguishing cytoskeletal and vesicle-trafficking proteins from metabolic and hepatic ones; the grouping is independent of gene function and of clinical classification, indicating convergence on shared downstream biology rather than gene-specific pathology. Epilepsy leaves a reproducible plasma signature detectable across disorders and largely independent of genotype, identifying candidate markers of seizure burden that are shared rather than syndrome specific. These proteomes also overlap those of adult neurodegenerative disease: most disorders are enriched against at least one signature of Alzheimer disease, Parkinson disease, frontotemporal dementia or amyotrophic lateral sclerosis, more often inversely than concordantly, placing early-life monogenic disorders on a shared axis with late-onset degeneration. A multivariate severity index built from plasma proteins tracks adaptive communication ability in disorders held out entirely from model training and distinguishes severity among individuals who share a diagnosis rather than only separating disorders from one another. Twenty-four of the prioritised cross-disorder proteins have a recorded drug interaction, several with agents already approved for other indications. Recruitment was concentrated at single sites for a subset of disorders, and results for those disorders are reported separately and descriptively throughout. Collectively, these findings support a shift from single-gene to pathway-based, cross-disorder trial strategies that leverage convergent biomarker panels and mechanistically informed, potentially repurposed interventions.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.767059
Primary Topic
Genetics and Neurodevelopmental Disorders
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A plasma proteomic atlas of rare genetic neurodevelopmental disorders reveals convergent molecular signatures, neurodegenerative overlap, and a cross-disorder severity index

Zollie A Yavarow, Joerg F. Hipp, Angela Duong, Jérémy Manry et al.
6 links
bioRxiv (Cold Spring Harbor Laboratory)
Genetics and Neurodevelopmental Disorders
preprint

A plasma proteomic atlas of rare genetic neurodevelopmental disorders reveals convergent molecular signatures, neurodegenerative overlap, and a cross-disorder severity index

Zollie A Yavarow, Joerg F. Hipp, Angela Duong, Jérémy Manry, Megan A. Aumann, Ananya Terala, Mariana Laranjo, Terry Jo Bichell, Sarah Poliquin, Wayne W. Poon, Kristin Hatcher, Rachael Elizabeth Hawtin, Lindsay Wieczorek, Natasha N. Ludwig, S. Jagadish, Marco Rizzo, Jennifer Bain, Jacqueline R. Harris, Albert L. Misko, Yael Weiss, Shruti Sasaki, Stephanie Szobota, Christopher L. Ricupero, Ricardo N. Ramírez, Anna C. Pfalzer, Elizabeth Berry Kravis, Berit E. Powers, Brett Younginger, Taylor Morris, Nichol Miller, William Keener, Sasha Elmizadeh, Nicole Davis, Nicholas Aguilar, Marie Elodie Cattin Messaoudi, Grace Viggiano, Kevin Wright
preprint en

Abstract

Rare genetic neurodevelopmental disorders are individually too small for well-powered biomarker studies, and each is typically studied alone. We present a harmonized plasma proteomic resource that treats them together: over 10,000 proteins measured across 27 rare genetic neurodevelopmental disorders and unaffected family members, 26 of them with enough participants for differential abundance analysis, paired with standardized adaptive behaviour phenotypes and released with the full analysis pipeline. Aggregating across disorders makes shared biology visible that single-disorder studies cannot resolve. Genetically distinct disorders converge onto two proteomic clusters separated along a single dominant axis, distinguishing cytoskeletal and vesicle-trafficking proteins from metabolic and hepatic ones; the grouping is independent of gene function and of clinical classification, indicating convergence on shared downstream biology rather than gene-specific pathology. Epilepsy leaves a reproducible plasma signature detectable across disorders and largely independent of genotype, identifying candidate markers of seizure burden that are shared rather than syndrome specific. These proteomes also overlap those of adult neurodegenerative disease: most disorders are enriched against at least one signature of Alzheimer disease, Parkinson disease, frontotemporal dementia or amyotrophic lateral sclerosis, more often inversely than concordantly, placing early-life monogenic disorders on a shared axis with late-onset degeneration. A multivariate severity index built from plasma proteins tracks adaptive communication ability in disorders held out entirely from model training and distinguishes severity among individuals who share a diagnosis rather than only separating disorders from one another. Twenty-four of the prioritised cross-disorder proteins have a recorded drug interaction, several with agents already approved for other indications. Recruitment was concentrated at single sites for a subset of disorders, and results for those disorders are reported separately and descriptively throughout. Collectively, these findings support a shift from single-gene to pathway-based, cross-disorder trial strategies that leverage convergent biomarker panels and mechanistically informed, potentially repurposed interventions.

bioRxiv (Cold Spring Harbor Laboratory)
Bial (Portugal) (PT), F. Hoffmann-La Roche AG (CH), Acadia Pharmaceuticals (United States) (US), Novartis (Switzerland) (CH), Kennedy Krieger Institute (US), Ionis Pharmaceuticals (United States) (US), Ultragenyx Pharmaceutical (United States) (US), Novartis (United States) (US), Servier (France) (FR), Field Foundation (US), Bial (Spain) (ES), Rush University (US), Columbia University (US), Vanderbilt University Medical Center (US)
FRAXA Research Foundation, Johns Hopkins University, University of Pittsburgh, Glut1 Deficiency Foundation
Good health and well-being
Genetics and Neurodevelopmental Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon